Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 9
Submit an article Journal homepage
330
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics in Solid Organ Transplantation: Genes Involved in Mechanism of Action and Pharmacokinetics of Immunosuppressive Drugs

Mateusz Kurzawski1 Department of Experimental & Clinical Pharmacology, Pomeranian Medical University, Powstancow Wlkp 72, 70–111Szczecin, Poland
&
Marek DroździkCorrespondence[email protected]
Pages 1099-1118 | Published online: 09 Jul 2013

References

  • Shiraga T , MatsudaH, NagaseK et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47(4) , 727–735 (1994).
  • Kuehl P , ZhangJ, LinY et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4) , 383–391 (2001).
  • Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
  • Hesselink DA , van Schaik RHN, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74(3) , 245–254 (2003).
  • Haufroid V , MouradM, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics14(3) , 147–154 (2004).
  • Tavira B , GarciaEC, Diaz-CorteC et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49(5) , 825–833 (2011).
  • Zhao W , FakhouryM, BaudouinV et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur. J. Clin. Pharmacol. 69(2) , 189–195 (2013).
  • Garcia-Roca P , MedeirosM, ReyesH et al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch. Med. Res.43(4) , 283–287 (2012).
  • Cho JH , YoonYD, ParkJY et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant. Proc. 44(1) , 109–114 (2012).
  • Niioka T , SatohS, KagayaH et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 94(10) , 1013–1019 (2012).
  • Glowacki F , LionetA, HammelinJP et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin. Pharmacokinet. 50(7) , 451–459 (2011).
  • Hashimoto H , ToideK, KitamuraR et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218(2) , 585–595 (1993).
  • Gervasini G , GarciaM, MaciasRM, CuberoJJ, CaravacaF, BenitezJ. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transplant. Int.25(4) , 471–480 (2012).
  • Elens L , van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors‘ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics12(10) , 1383–1396 (2011).
  • Saeki T , UedaK, TanigawaraY, HoriR, KomanoT. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem.268(9) , 6077–6080 (1993).
  • Kimchi-Sarfaty C , OhJM, KimIW et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811) , 525–528 (2007).
  • Li D , GuiR, LiJ, HuangZ, NieXM. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant. Proc.38(9) , 2850–2852 (2006).
  • Akbas SH , BilgenT, KeserI et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant. Proc. 38(5) , 1290–1292 (2006).
  • Haufroid V , MouradM, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogeneticss14(3) , 147–154 (2004).
  • Kuypers DR , NaesensM, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit.32(4) , 394–404 (2010).
  • Li Y , HuX, CaiB et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transplant. Immunol. 27(1) , 12–18 (2012).
  • de Jonge H , MetalidisC, NaesensM, LambrechtsD, KuypersDR. The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics12(9) , 1281–1291 (2011).
  • Boivin AA , CardinalH, BaramaA et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug. Metab. Pharmacokinet. doi:http://dx.doi.org/10.2133/dmpk.DMPK-12-SH-093 (2012) (Epub ahead of print).
  • Shitara Y , TakeuchiK, NagamatsuY, WadaS, SugiyamaY, HorieT. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug. Metab. Pharmacokinet.27(4) , 368–378 (2012).
  • Birdwell KA , GradyB, ChoiL et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22(1) , 32–42 (2012).
  • Thervet E , LoriotMA, BarbierS et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6) , 721–726 (2010).
  • Passey C , BirnbaumAK, BrundageRC, OettingWS, IsraniAK, JacobsonPA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol.72(6) , 948–957 (2011).
  • Elens L , HesselinkDA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br. J. Clin. Pharmacol. (2012).
  • Quteineh L , VerstuyftC, FurlanV et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6) , 546–552 (2008).
  • Min SI , KimSY, AhnSH et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation90(12) , 1394–1400 (2010).
  • Miura Y , SatohS, SaitoM et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. Transplantation 91(1) , 78–85 (2011).
  • Naesens M , LerutE, de Jonge H et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol.20(11) , 2468–2480 (2009).
  • Miao LY , HuangCR, HouJQ, QianMY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm. Drug Dispos.29(1) , 1–5 (2008).
  • Sam WJ , ChamberlainCE, LeeSJ et al. Associations of ABCB1 3435C > T and IL-10-1082G > a polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation 92(12) , 1342–1347 (2011).
  • Mourad M , MouradG, WallemacqP et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80(7) , 977–984 (2005).
  • Moes D , PressRR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin. Pharmacokinet.51(7) , 467–480 (2012).
  • Tett SE , Saint-MarcouxF, StaatzCE et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant. Rev. (Orlando) 25(2) , 47–57 (2011).
  • Basu NK , KoleL, KubotaS, OwensIS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug. Metab. Dispos.32(7) , 768–773 (2004).
  • Picard N , RatanasavanhD, PremaudA, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos.33(1) , 139–146 (2005).
  • Kuypers DR , de Jonge H, Naesens M et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther.30(4) , 673–683 (2008).
  • van Schaik RHN , van Agteren M, de Fijter JW et al.UGT1A9 -275T>A/-2152C>T Polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther.86(3) , 319–327 (2009).
  • Sanchez-Fructuoso AI , MaestroML, CalvoN et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant. Proc. 41(6) , 2313–2316 (2009).
  • Johnson LA , OettingWS, BasuS, PrausaS, MatasA, JacobsonPA. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur. J. Clin. Pharmacol.64(11) , 1047–1056 (2008).
  • Kobayashi M , SaitohH, TadanoK, TakahashiY, HiranoT. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J. Pharmacol. Exp. Ther.309(3) , 1029–1035 (2004).
  • Miura M , KagayaH, SatohS et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug. Monit. 30(5) , 559–564 (2008).
  • Baldelli S , MerliniS, PericoN et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8(9) , 1127–1141 (2007).
  • Lloberas N , TorrasJ, CruzadoJM et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the pharmacogenomic substudy within the symphony study. Nephrol. Dial. Transplant. 26(11) , 3784–3793 (2011).
  • Shipkova M , ArmstrongVW, OellerichM, WielandE. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit.25(1) , 1–16 (2003).
  • Naesens M , KuypersDR, VerbekeK, VanrenterghemY. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation82(8) , 1074–1084 (2006).
  • Woillard JB , RerolleJP, PicardN et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br. J. Clin. Pharmacol. 69(6) , 675–683 (2010).
  • Miura M , SatohS, InoueK et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(12) , 1161–1169 (2007).
  • Wang J , YangJW, ZeeviA et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther.83(5) , 711–717 (2008).
  • Kagaya H , MiuraM, SaitoM, HabuchiT, SatohS. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin. Pharmacol. Toxicol.107(2) , 631–636 (2010).
  • Grinyo J , VanrenterghemY, NashanB et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl. Int. 21(9) , 879–891 (2008).
  • Sombogaard F , van Schaik RH, Mathot RA et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet. Genomics19(8) , 626–634 (2009).
  • Halloran P , MathewT, TomlanovichS, GrothC, HooftmanL, BarkerC. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation63(1) , 39–47 (1997).
  • Weinshilboum RM , SladekSL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum.Genet.32(5) , 651–662 (1980).
  • Kurzawski M , DziewanowskiK, CiechanowskiK, DrozdzikM. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C). Transpl. Int.18(5) , 623–625 (2005).
  • Budhiraja P , PopovtzerM. Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A. Nat. Rev. Nephrol.7(8) , 478–484 (2011).
  • Yates CR , KrynetskiEY, LoennechenT et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8) , 608–614 (1997).
  • Stocco G , FrancaR, VerzegnassiF, LonderoM, RabusinM, DecortiG. Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front. Genet.3 , 309 (2012).
  • Relling MV , GardnerEE, SandbornWJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3) , 387–391 (2011).
  • Formea CM , Myers-HuentelmanH, WuR et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am. J. Transplant. 4(11) , 1810–1817 (2004).
  • Kurzawski M , DziewanowskiK, Gawronska-SzklarzB, DomanskiL, DrozdzikM. The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther. Drug Monit.27(4) , 435–441 (2005).
  • Kurzawski M , DziewanowskiK, LenerA, DrozdzikM. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur. J. Clin. Pharmacol.65(5) , 533–540 (2009).
  • Xin HW , XiongH, WuXC, LiQ, XiongL, YuAR. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol.65(3) , 249–255 (2009).
  • Vannaprasaht S , AngsuthumS, AvihingsanonY et al. Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand. Clin. Ther. 31(7) , 1524–1533 (2009).
  • Fabre MA , JonesDC, BunceM et al. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transpl. Int. 17(9) , 531–539 (2004).
  • Song DK , ZhaoJ, ZhangLR. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment. J. Clin. Pharm. Ther.31(6) , 627–635 (2006).
  • von Ahsen N , OellerichM, ArmstrongVW. Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther. Drug Monit.30(1) , 16–22 (2008).
  • van Dieren JM , HansenBE, KuipersEJ, NieuwenhuisEE, van der Woude CJ. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther.26(5) , 643–652 (2007).
  • Xiong H , XinHW, WuXC, LiQ, XiongL, YuAR. Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients. Fundam. Clin. Pharmacol.24(3) , 393–400 (2010).
  • Kurzawski M , DziewanowskiK, SafranowK, DrozdzikM. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. Ther. Drug Monit.34(3) , 266–274 (2012).
  • Miura M , SatohS, InoueK et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 73(11) , 1052–1059 (2008).
  • Wiesner RH , FungJJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl.17(Suppl. 3) , S1–S9 (2011).
  • Tisone G , OrlandoG, AngelicoM. Operational tolerance in clinical liver transplantation: emerging developments. Transpl. Immunol.17(2) , 108–113 (2007).
  • Shi Y , LiY, TangJ et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 512(2) , 226–231 (2013).
  • Yu XB , XieHY, WeiBJ et al. Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS ONE 6(11) , e25933 (2011).
  • Uesugi M , MasudaS, KatsuraT, OikeF, TakadaY, InuiKI. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics16(2) , 119–127 (2006).
  • Fukudo M , YanoI, YoshimuraA et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 18(5) , 413–423 (2008).
  • Muraki Y , UsuiM, IsajiS et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann. Transplant. 16(4) , 55–62 (2011).
  • Provenzani A , NotarbartoloM, LabbozzettaM et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann. Transplant. 14(1) , 23–31 (2009).
  • Barrera-Pulido L , Aguilera-GarciaI, Docobo-PerezF et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant. Proc. 40(9) , 2949–2951 (2008).
  • Bonhomme-Faivre L , DevocelleA, SalibaF et al. MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation78(1) , 21–25 (2004).
  • Hebert MF , DowlingAL, GierwatowskiC et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13(11) , 661–674 (2003).
  • Breen DP , MarinakiAM, ArenasM, HayesPC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transplant.11(7) , 826–833 (2005).
  • Buster EH , van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol.20(1) , 68–72 (2008).
  • Kniepeiss D , RennerW, TrummerO et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin. Transplant. 25(1) , 146–150 (2011).
  • Diaz-Molina B , TaviraB, LambertJL, BernardoMJ, AlvarezV, CotoE. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant. Proc.44(9) , 2635–2638 (2012).
  • Taegtmeyer AB , BreenJB, SmithJ et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation 89(1) , 75–82 (2010).
  • Chowbay B , CumaraswamyS, CheungYB, ZhouQ, LeeEJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics13(2) , 89–95 (2003).
  • Hesselink DA , van Gelder T, van Schaik RH et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther.76(6) , 545–556 (2004).
  • Ting LS , Benoit-BiancamanoMO, BernardO, RiggsKW, GuillemetteC, EnsomMH. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Pharmacotherapy30(11) , 1097–1108 (2010).
  • Ohmann EL , BurckartGJ, BrooksMM et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J. Heart Lung Transplant. 29(5) , 509–516 (2010).
  • Ohmann EL , BurckartGJ, ChenY et al. Inosine 5´-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients. Pediatr. Transplant. 14(7) , 891–895 (2010).
  • Sebbag L , BoucherP, DaveluP et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipient. Transplantation 69(7) , 1524–1527 (2000).
  • Zheng HX , ZeeviA, SchuetzE et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44(2) , 135–140 (2004).
  • Wang J , ZeeviA, McCurryK et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5*3/*3 nonexpressors. Transplant. Immunol. 15(3) , 235–240 (2006).
  • Zheng HX , ZeeviA, McCurryK et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transplant. Immunol. 14(1) , 37–42 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.